China Economic Network, Beijing, February 12-Rendu Biology (688193.SH) Annual Performance Forecast for 2023 shows that according to preliminary calculations by the financial department, the company expects the net profit attributable to the owner of the parent company to be 2.3 million yuan to 3.4 million yuan in 2023, which will decrease by 2,103 to 19.93 million yuan and 90% to 85% year on year compared with the same period last year (statutory disclosure data); it is estimated that the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses in 2023 will be -13.47 million yuan to -12.37 million yuan, which will decrease by 18.41 million yuan to 17.31 million yuan compared with the same period last year (statutory disclosure data), and a year-on-year decrease. 373 to 350. This performance forecast has not been audited by a certified public accountant.

Rendu Bio's 2022 annual report shows that the company achieved operating income of 0.304 billion yuan last year, up 3.95 percent from the same period last year; net profit attributable to shareholders of listed companies was 23.3314 million yuan, down 63.89 percent from the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 4.9396 million yuan, down 91.39 percent from the same period last year; net cash flow from operating activities was 4.0912 million yuan, down 107.51 percent from the same period last year.

Rendu Bio will be listed on the SSE on March 30, 2022 at a price of 72.65 yuan per share. On the day of listing, Rendu Bio fell below the issue price at the opening price of 68.00 yuan, down 6.40 percent, and then broke throughout the day, closing at 64.76 yuan, down 10.86 percent. In addition, Rendu Biology hit a high price of 72.00 yuan on its first day of listing, after which the stock fluctuated lower.

Rendu Bio issued 10 million new shares, accounting for 25.00 per cent of the total number of shares issued by the Company. The total amount of funds raised by Rendu Bio was 726.5 million yuan, and after deducting the issuance expenses, the net amount of funds raised was 652.7649 million yuan. Rendu Bio's actual net fund-raising is 47.7459 million yuan less than the original proposed fund-raising. The company's prospectus disclosed on March 25, 2022 shows that Rendu Bio originally intends to raise 700.5108 million billion yuan, which is intended to be used for "precision diagnostic reagents and intelligent equipment industrialization research and development projects" and "marketing network construction projects" respectively ".

Rendu Bio's sponsor is CICC, and the sponsor representatives are Fan Yukun and Wei Dejun. The total issuance fee is 73.7351 million yuan, of which the sponsorship and underwriting fee is 52.308 million yuan.

Rendu Biology disclosed on February 7, 2024 that the chairman and actual controller of the company proposed the company to buy back shares and the company implemented the action plan of "improving quality, increasing efficiency and paying attention to returns". On February 6, 2024, the company received the letter on proposing Shanghai Rendu Biotechnology Co., Ltd. to buy back shares of the company submitted by Mr. Jin Liang, chairman and actual controller of the company. The total amount of proposed repurchase funds shall not be less than 25 million yuan (inclusive) and not more than 50 million yuan (inclusive); the upper limit of the proposed repurchase price shall not be higher than 150 of the average trading price of the company's shares in the 30 trading days before the board of directors deliberated and approved the repurchase plan, which shall be subject to the repurchase plan deliberated and approved by the board of directors; the source of proposed repurchase funds: the RMB ordinary shares (A shares) issued by the company; the purpose of the proposed share repurchase: the repurchased shares will be used for employee stock ownership plans or equity incentives at an appropriate time in the future, as well as for safeguarding the value of the company and shareholders' rights and interests. The specific purpose shall be determined by the board of directors of the company in accordance with relevant laws and regulations; the method of proposing share repurchase: within 6 months from the date of consideration and approval of the share repurchase plan by the Board of Directors of the Company.